SAN DIEGO --(BUSINESS WIRE)--Jun. 27, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of RSM US LLP (“RSM”) as its independent registered public accounting firm effective June 24, 2022 .
Industry veteran to oversee operations for the company and its CNSide™ cerebrospinal fluid assay to aid in the management of patients with metastatic brain cancers SAN DIEGO --(BUSINESS WIRE)--Mar. 8, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products
SAN DIEGO , Feb. 15, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces the appointment of Michael Terry to the newly
Biocept Appoints Michael Nall as CEO Biocept, Inc. announced today that it has appointed Michael W. Nall as President and Chief Executive Officer. Mr. Nall’s extensive commercialization, sales and marketing experience will be a significant asset as the company brings its pipeline of OncoCEETM
SAN DIEGO --(BUSINESS WIRE)--Nov. 18, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately, increasing Board membership to eight. Ms.
SAN DIEGO , Oct. 27, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces the appointment of David
SAN DIEGO , Feb. 14, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the promotion of Cory J.